In esophageal squamous cell cancer, gastrointestinal stromal tumor, head and neck squamous cell carcinoma, and pancreatic and breast cancers, it has been suggested that the amplification of TMEM16A could serve as a biomarker [70]. Here, ANO1 is linked to breast cancer.